Search Results
Mar 12, 2026, 16:33 ET ImmunoBrain to Present Topline Phase 1b Clinical Data for Immune Checkpoint Treatment in Alzheimer's Disease at AD/PD™ 2026
are as follows:Session Name: Mechanistic Modifiers of AD: APOE, Immunity, and Neural CircuitsTitle: PD-L1 Immune Checkpoint Blockade in Early Alzheimer's Disease: Topline Results from the Phase 1b IBC-01-01 Study (ID 2979)Date and Time: Thursday,
More news about: ImmunoBrain Checkpoint Inc.
Mar 12, 2026, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of GBM. The combination therapy will be studied as a part of the INdividualized Screening trial
More news about: INOVIO Pharmaceuticals, Inc.
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elevance Health, Inc. - ELV
its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company's Medicare Advantage-Prescription Drug ('MA-PD') plans and suspending certain communication activities to Medicare beneficiaries." Elevance said that "CMS has indicated that the proposed sanctions
More news about: Pomerantz LLP
Mar 12, 2026, 08:15 ET Constructor Reports 82% Customer Growth in FY26, With its Platform Powering 322 Billion Shopping Interactions
shopper expectations continue to rise, ecommerce companies are turning to search and product discovery (S&PD) as a key performance driver. According to Gartner®: "Demand for differentiating S&PD continues to grow. It is often seen as a relatively cost-effective way to provide optimal experiences
More news about: Constructor
Mar 12, 2026, 07:30 ET Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates range from 50 to 65%, depending on tumor size. Rates are generally lower in the larger-sized tumors or
More news about: Intensity Therapeutics Inc.
Mar 11, 2026, 23:21 ET Un patient américain atteint d'un cancer du poumon avancé est stabilisé par un nouveau traitement d'immunothérapie en Chine
de traitement standard au MD Anderson Cancer Center aux États-Unis. Ses médecins lui ont recommandé l'ivonescimab, le premier anticorps bispécifique PD-1/VEGF approuvé pour les tumeurs solides. Après une consultation vidéo fin novembre, programmée dans la semaine suivant leur demande initiale, la famille
More news about: Jiahui International Hospital
Mar 11, 2026, 08:30 ET Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
Monday PM - Bone and Soft Tissue Pathology. March 23, 2026. Time: 1:00 PM – 4:30 PM CDTInterplay of Programmed Death-Ligand 1 (PD-L1) Expression in Gastrointestinal Stromal Tumor (GIST): Correlation with Clinicopathologic Features, Comprehensive Genomic Profile, and Disease Outcome.
More news about: Caris Life Sciences
Mar 11, 2026, 03:28 ET Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
https://news.cision.com/bioarctic/r/latest-data-on-long-term--real-world-treatment-with-lecanemab-will-be-presented-at-the-ad-pd--2026-c,c4319514The following files are available for download:
More news about: BioArctic
Mar 11, 2026, 03:25 ET Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
https://news.cision.com/bioarctic/r/latest-data-on-long-term--real-world-treatment-with-lecanemab-will-be-presented-at-the-ad-pd--2026-c,c4319514The following files are available for download:
More news about: BioArctic
Mar 10, 2026, 19:30 ET Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
Biomarkers and ImagingGenomic Landscapes in AD, PD and Dementia Wednesday, March 18, 16:15-16:30
More news about: Eisai Inc.
Mar 10, 2026, 17:11 ET Franco-Nevada Reports Record 2025 Results
thereof.Our 2026 guidance and five-year outlook are based on the following assumed commodity prices: $4,500/oz Au, $75.00/oz Ag, $2,000/oz Pt, $1,650/oz Pd, $100/tonne Fe 62% CFR China, $70/bbl WTI oil and $3.00/mcf Henry Hub natural gas.2026 GuidanceBeginning in 2026, we will be adopting
More news about: Franco-Nevada Corporation
Mar 10, 2026, 15:21 ET Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
based on type, application, sales channel, and geography.By Type, the market includes CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, and Others.By Application, the market includes Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer,
More news about: Credence Research Inc.
Mar 10, 2026, 10:28 ET Power Metallic Intercepts 16.55 Meters of 15.11% CuEqRec¹ in Hole 25-049, and 7.60 Meters of 7.20% CuEqRec¹ in Hole 25-043 at Lion
CuPdPt
More news about: Power Metallic Mines Inc.
Mar 10, 2026, 09:15 ET New AI Solution Helps Predict Which Lung Cancer Patients Will Benefit from Immunotherapy
directing patients to their best care."Beyond Existing BiomarkersCurrent tests used to guide immunotherapy decisions, such as PD-L1 testing, focus mainly on immune markers unique to tumor cells. However, they overlook another important factor: the network of blood vessels supplying
More news about: Picture Health
Mar 10, 2026, 08:47 ET Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
investigators. This study evaluated the direct T-regulatory (Treg) cell depletion activity of LYMPHIR™ (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) in patients with recurrent or refractory gynecologic cancers, including ovarian and
More news about: Citius Oncology, Inc.
Mar 09, 2026, 15:15 ET Solution Tree Acquires Dirigo Literacy, Expanding Comprehensive K-12 Literacy Solutions
Global PD Teams and
More news about: Solution Tree
Mar 09, 2026, 11:50 ET SIG SAUER Expands Shooter Affiliate Program to include Sal Hernandez, Ian Meyers, and Kevin Lally
Master class competitor in USPSA and competes in pistol, 2-gun, and Multi-gun competitions around the country.Kevin Lally is a former Metropolitan PD officer currently serving as a SWAT operator and instructor for a local NH police department. He is a Master class USPSA and IDPA competitor in multiple
More news about: SIG SAUER, Inc.
Mar 09, 2026, 08:00 ET AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. ABBV-295 is a long-acting amylin analog that
More news about: AbbVie
Mar 09, 2026, 07:15 ET MWC Barcelona 2026: Start der nubia Neo 5-Serie mit dem einzigen integrierten Lüfter in dieser Klasse
anhält, verfügt das nubia Neo 5 GT über einen leistungsstarken 6210-mAh-Dual-Cell-Akku, gepaart mit einer Super-Schnellladefunktion von bis zu 80 W (45 W PD für den EU-Markt). Für Vielspieler versorgt die Bypass-Ladefunktion das Telefon direkt mit Strom, ohne den Akku während des Spielens aufzuladen.Immersives
More news about: ZTE Corporation
Mar 09, 2026, 05:20 ET nubia Neo 5 Series Diluncurkan di MWC Barcelona 2026 dengan Kipas Pendingin Bawaan, Inovasi Satu-Satunya di Kelasnya
mendukung sesi bermain gim dengan durasi lama, nubia Neo 5 GT dibekali baterai dual-cell 6.210 mAh dengan fitur pengisian daya cepat hingga 80W (45W PD untuk pasar Uni Eropa). Dengan fitur Bypass Charging, perangkat memperoleh pasokan daya secara langsung dari adaptor tanpa harus mengisi daya
More news about: ZTE Corporation
Mar 09, 2026, 02:41 ET Un paciente estadounidense recibe un nuevo tratamiento de inmunoterapia para el cáncer de pulmón en China
tratamientos habituales en el MD Anderson Cancer Center de Estados Unidos. Sus médicos le recomendaron ivonescimab, el primer anticuerpo biespecífico PD 1/VEGF aprobado para tumores sólidos. Tras una videoconsulta a finales de noviembre, programada una semana después de su consulta inicial, la familia
More news about: Jiahui International Hospital
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
effector T-cell populations within the tumor microenvironment, Opamtistomig has the potential to deliver more potent and durable anti-tumor activity than PD-1/PD-L1 blockade alone, particularly in difficult-to-treat and immunotherapy-resistant tumors. To date, Opamtistomig has demonstrated first- or best-in-class
More news about: Leads Biolabs
Mar 08, 2026, 20:45 ET US-Patient mit fortgeschrittenem Lungenkrebs durch neuartige Immuntherapie-Behandlung in China stabilisiert
Standardbehandlungen im MD Anderson Cancer Center in den Vereinigten Staaten ausgeschöpft. Seine Ärzte empfahlen Ivonescimab, den ersten zugelassenen bispezifischen PD-1/VEGF-Antikörper für solide Tumore. Nach einer Videokonsultation Ende November, die innerhalb einer Woche nach der ersten Anfrage stattfand, entschied
More news about: Jiahui International Hospital
Mar 07, 2026, 10:16 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD‑1/VEGF bispecific antibody for solid tumors. After a video consultation in late November scheduled within a week of their initial inquiry, the family
More news about: Jiahui International Hospital
Mar 06, 2026, 23:20 ET U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China
exhausted all standard lines of treatment at MD Anderson Cancer Center in the United States. His doctors recommended ivonescimab, the first approved PD‑1/VEGF bispecific antibody for solid tumors. After a video consultation in late November scheduled within a week of their initial inquiry, the family
More news about: Jiahui International Hospital